CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Save this PDF as:

Size: px
Start display at page:

Download "CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk"

Transcription

1 VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp,

2 CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffkyc, Ps; Peptostreptococcus

3 VOL. 30 S-3 CHEMOTHERAPY Table 2 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: B; Bacteroides, F; Fusobacterium, E ; Eubacterium, P; Propionibacterium C; Clostridium, *V; Veillonella, **V; Vibrio

4 CHEMOTHERAPY DEC Table 3 Antibacterial activity of T-1982 against anaerobic bacteria Table 4 Antibacterial activity of T-1982 against anaerobic bacteria Note: Sensitivity test media; Brucella blood agar Incubation; 24 hours in an anaerobic cham - ber P; Peptococcus, S; Streptococcus, G; Gaffkya Ps; Peptostreptococcus ; 24 hours in an anaero- (Difco), Incubation bic chamber Note: Sensitivity test media ; Brucella blood agar B ; Bacteroides, F ; Fusobacterium **V ; Vibrio,, *V ; Veillonella, E; Eubacterium, P ; Propionibacterium, C ; Clostridium

5 VOL.30 S-3 CHEMOTHERAPY Table 5 Antimicrobial activity of T-1982 and other three antimicrobials against Bacteroides fragilis (26 strains) Table 6 Antimicrobial activity of T-1982 and other three antimicrobials against Peptococcus magnus (21 strains) Table 7 Antimicrobial activity of T-1982 and other three antimicrobials against Peptococcus asaccharolyticus (8 strains)

6 CHEMOTHERAPY DEC Table 8 Antimicrobial activity of T-1982 and other three antimicrobials against Peptostreptococcus sp.*(17 strains) *Ps. parvulus, Ps. anaerobius, Ps. micros, S. constellatus, S. intermedius, S. morbillorum, Peptostreptococcus sp. Table 9 Antimicrobial activity of T-1982 and other three antimicrobials against Veillonella parvula (14 strains) Table 10 Antimicrobial activity of T-1982 and other three antimicrobials against Clostridium difficile (20 strains)

7 CHEMOTHERAPY Fig. 1 Development of resistance of Bacteroides fragilis (GAI-0562) to T-1982, LMOX and CEZ Fig. 3 Ĉ-lactamase activity of Bacteroides fragilis (GAI-0830) 5.30 U/mg of protein Hydrolysis of CEZ=100 Fig. 4 Ĉ-lactamase activity of Bacteroides fragilis (GAI-0548) Fig. 2 Development of resistance of Bacteroides fragilis (GAI-0548) to T-1982, LMOX and CEZ 0.85 U/mg of protein Hydrolysis of CEZ=100

8 CHEMOTHERAPY DEC Fig. 5 j9-lactamase activity fragilis (GAI-0556) of Bacteroides Fig. 8 Morphological changes at various concentration of T-1982, LMOX and CEZ Fig. 6 P-Lactamase activity of Bacteroides fragilis (GAI-0511) Fig. 9 Morphological changes at various concentration of T-1982, LMOX and CEZ Fig. 7 /9-Lactamase activity fragilis (GAI-0763) of Bacteroides

9 CHEMOTHERAPY Fig.10 Appearance of Clostridium difficile in caecum contents of mice administrated various cephem-antibiotics Table 11 In vivo activity of T-1892 against Bacteroides fragilis (GAI-0558) B. fragilis; 108 CFU/mouse i. p. Grade of recovery of B. fragilis; to Table 12 In vivo activity of T-1982 against Bacteroides fragilis (GAI-0558) Medication: dose; 2 mg/day, route; S. C., term; 7 days *4+: 104 or more/plate, 3+: 104 `103/plate, 2+: 103 `102/plate, 1+: 102 `10 /plate,-: no growth B. fragilis; 108 CFU/mouse i. p. Grade of recovery of B. fragilis; -FFE to

10 CHEMOTHERAPY

11 CHEMOTHERAPY ANTIBACTERIAL ACTIVITY OF T-1982 AGAINST ANAEROBES KUNITOMO WATANABE, MIDORIISONO, MAKOTO AOKI TOYOKO KOBAYASHI and KAZUE UENO Institute of Anaerobic Bacteriology, Gifu University, School of Medicine The antibacterial activity of T-1982, a new cephamycin antibiotic, was studied. The following results were obtained. 1) The antibacterial spectrum of T-1982 against anaerobes was almost conformable to that of cefmetazole and cefotetan. Its antibacterial activity against B. fragilis was slightly more potent than that of cefmetazole and cefotetan, with the MIC of ƒÊg/ml. Against anaerobic cocci, T-1982 was less active than cefazolin, cefotaxime and cefoperazone but comparable to cefmetazole and cefotetan. The activity was weak against B. thetaiotaomicron, E. lentum, C.difficile and C. rarnosum. 2) Like cefmetazole and cefotetan, T-1982 was very stable to ƒà-laatamase produced by B. fragilis. 3) In the bouillon containing T-1982 (at the MIC), B. fragilis was almost completely lyzed and filamentation was scarcely observed. 4) In the broth containing T-1,982, resistance of B. fragilis was gradually increased with the passage of culture. 5) Following s.c. administration of T-1982 at a dose of 2 mg for 7 days in mice, abnormal growth rate of (C. difficile was 80% in the,cecum, although the number of organisms detected was extremely small. 6) T-1982 exhibited potent in vivo antibacterial activity against B. fragilis intraperitoneally inoculated in mice.

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

More information

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

More information

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,

More information

CHEMOTHERAPY 34 T-2588の APR.1986 嫌 気 性 菌 に 対す る抗 菌 作 用 に つ い て 沢 赫 代 神 野 英 毅 青 木 誠 小 林 と よ子 渡 辺 邦 友 上 野 一 恵 岐阜大学医学部附属嫌気性菌実験施設 新 し く 開 発 さ れ た 経 口 用 エ ス テ ル 型 セ フ ェ ム 系 抗 生 剤T-2588の 口 剤 で あ るcephalexin(CEX),cefaclor(CCL)

More information

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

More information

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

More information

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

More information

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330) CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column

More information

日本化学療法学会雑誌第53巻第S-3号

日本化学療法学会雑誌第53巻第S-3号 moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium

More information

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

More information

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT

More information

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

More information

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.); VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

More information

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

More information

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

More information

Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against

More information

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

More information

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic

More information

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

More information

Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse

Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse Table 1 Susceptibility to various antibiotics Antibiotics Abbreviations ABPC: GM: CET: CEZ: CMZ: LMOX: CMX: Bacteriae used Ampicillin

More information

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

More information

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega 1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

More information

VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence

More information

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

More information

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, MBC, MIC of drugs in combination Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar

More information

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

More information

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae

More information

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY

More information

Fig. 1 Chemical structure of KW-1070

Fig. 1 Chemical structure of KW-1070 Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

More information

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

More information

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

More information

Table 1. Antibacterial activity of azithromycin and other agents against gram-positive anaerobic bacteria and facultative anaerobic bacteria a Facultative anaerobic bacteria. Table 2. Antibacterial activity

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against

More information

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii

More information

Table1MIC of BAY o 9867 against standard strains

Table1MIC of BAY o 9867 against standard strains Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative

More information

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2

More information

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45) Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE

More information

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

More information

Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;

More information

Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic

More information

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

More information

VOL.42 S-1

VOL.42 S-1 CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical

More information

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

More information

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels

More information

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients

More information

2 CHEMOTHERAPY JAN. 1976 VOL. 24 NO. 1 CHEMOTHERAPY 3 Table 1 Antibacterial spectra of Cephacetrile, Cephalothin, Cephaloridine and Cefazolin 4 CHEMOTHERAPY JAN. 1976 Fig. 1 In vitro activity of Cephacetrile,

More information

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized

More information

Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background

More information

CHEMO THE RAPY OCT. 1994

CHEMO THE RAPY OCT. 1994 bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri

More information

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3 VOL. 20 NO. 5 CHEMOTHERAPY 653 2-Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3376, SDM, SIZ and SMZ against Gram-positive and negative

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics

More information

1) Chemical name: Fig. 1 Chemical structure of TE-031 (-)-(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2, PYranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-meth 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexo- oxy-3,5,7,9,11,13-hexamethy1-6-[[3,4,6-trideoxy-3-

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

More information

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

More information

2.7 臨床概要

2.7 臨床概要 2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis

More information

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference

More information

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis

More information

VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3

More information

CHEMOTHERAPY APR. 1982

CHEMOTHERAPY APR. 1982 VOL.30 S-1 CHEMOTHERAPY Table 1 Dose of CTT and subjects i. v.: Intravenous bolus injection d. i. v.: Intravenous drip infusion i. m.: Intramuscular injection Fig. 1 Schedule for examination of CTT, 1.0g

More information

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella

More information

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)

More information

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration

More information

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor

More information

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57) CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57) VOL.30 S-1 CHEMOTHERAPY Table 1 Method of HPLC-assay of CTT and its

More information

日本化学療法学会雑誌第61巻第6号

日本化学療法学会雑誌第61巻第6号 β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

More information

CHEMOTHERAPY MAY 1988 Table 1 Media used for preculture and MIC determination *BHIB: Brain heart infusion broth (Difco), B-NAD: B-Nicotinamide adenine dinucleotide (Sigma chemical Co.), GAMB GAM broth

More information

VOL. 36 S-3 CHEMOTHERAPY 437

VOL. 36 S-3 CHEMOTHERAPY 437 VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,

More information

03-b-„FŒ{›xŒ¾-4.02

03-b-„FŒ{›xŒ¾-4.02 518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus

More information

02-(a)-Łi’ì™·Łv-4.11

02-(a)-Łi’ì™·Łv-4.11 THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus

More information

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6 VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6- O-[3-deoxy-4 -C-methyl-3 -(methylamino) -ƒà-l- arabinopyranosyl]-2

More information

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky 2.7 2.7.5 1) 199846410-437 2) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) 1986 34408-441 3) () 199745762-778 4) 1992 5) 199543 6) Chemotherapy (Tokyo) 199139687-689 7) Imipenem/Cilastatin sodium (MK-0787/MK-0791)

More information

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

More information

VOL. 28 S-2 CHEMOTHERAPY

VOL. 28 S-2 CHEMOTHERAPY VOL. 28 S-2 CHEMOTHERAPY CHEMOTHERAPY 52 (Oxaciliin hydrolysing Enterobacter cloacae P.mirabilis GN79, sp.gn69,お enzyme)の Nek E.ooli よ びE.coli た GN番 産 生 菌 と し て, 39, Proteus CSH vulgaris 2 (RK1), ML1410

More information

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3- Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,

More information

日本化学療法学会雑誌第57巻第S-2号

日本化学療法学会雑誌第57巻第S-2号 µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3

More information

渡辺(2309)_渡辺(2309)

渡辺(2309)_渡辺(2309) [ 29 p. 241-247 (2011)] ** *** ** ** Development of a nickel-based filler metal containing a small amount of silicon by WATANABE Takehiko, WAKATSUKI Ken, YANAGISAWA Atsusi and SASAKI Tomohiro Authors tried

More information

Key words: Surfactant, Tween, Legionella

Key words: Surfactant, Tween, Legionella Key words: Surfactant, Tween, Legionella Fig. 1 Inhibitory Activity of Various Tween Against Legionella pneumophila Fig. 2 Inhibitory Activity of Various Tween Against Legionella bozemanii Fig. 3 Inhibitory

More information

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus

More information

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum

More information

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of 4.9 g Mezlocillin Streptococcus pneumonzae pneumoniae

More information

Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)

More information

CHEMOTHERAPY NOV Fig.1 Combined effect of drug A and drug B Fig. 2 MICs of CEPs (LMOX, CZX, CMX, CPZ) against 27 strains (inoculum size 106 CFU/

CHEMOTHERAPY NOV Fig.1 Combined effect of drug A and drug B Fig. 2 MICs of CEPs (LMOX, CZX, CMX, CPZ) against 27 strains (inoculum size 106 CFU/ CHEMOTHERAPY NOV. 1987 Fig.1 Combined effect of drug A and drug B Fig. 2 MICs of CEPs (LMOX, CZX, CMX, CPZ) against 27 strains (inoculum size 106 CFU/ml) of S. marcescens + Visible growth No visible growth

More information

感染症学雑誌第80巻第2号

感染症学雑誌第80巻第2号 Bacteroides Atopobium vaginae Bacteroides Atopobium vaginae 1 Bacteroides Bacteroides fragilis Bacteroides Bacteroides B. fragilis B. fragilis B. fragilis B. fragilis Bacteroides 2 Bacteroides Prevotella

More information

CHEMOTHERAPY FEB Table 1 Background of volunteers

CHEMOTHERAPY FEB Table 1 Background of volunteers CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels

More information

Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal

More information

Fig.1 Structural formulas of 6059-S(I) and decarboxylated product (11) Fig.2 Standard curve of 6059-S by agar well method Medium:Trypto-soy agar Diluent:0.1M Phosphate buffer,ph 7.0 Fig.3 Standard curves

More information

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof 242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF

More information